Menta Capital LLC trimmed its holdings in VIVUS, Inc. (NASDAQ:VVUS) by 2.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 286,972 shares of the biopharmaceutical company’s stock after selling 6,700 shares during the period. Menta Capital LLC owned about 0.27% of VIVUS worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of VVUS. Spark Investment Management LLC acquired a new position in VIVUS in the second quarter valued at about $100,000. Bank of New York Mellon Corp increased its holdings in shares of VIVUS by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 3,694 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of VIVUS by 84.8% in the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 68,200 shares in the last quarter. Oxford Asset Management raised its position in shares of VIVUS by 76.6% during the first quarter. Oxford Asset Management now owns 587,535 shares of the biopharmaceutical company’s stock worth $658,000 after purchasing an additional 254,912 shares during the period. Finally, Acadian Asset Management LLC raised its position in shares of VIVUS by 70.9% during the second quarter. Acadian Asset Management LLC now owns 1,837,822 shares of the biopharmaceutical company’s stock worth $2,241,000 after purchasing an additional 762,392 shares during the period. 35.82% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/vivus-inc-vvus-holdings-trimmed-by-menta-capital-llc/1604983.html.

Several equities analysts have recently weighed in on the company. Zacks Investment Research upgraded VIVUS from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Thursday, July 27th. ValuEngine cut VIVUS from a “buy” rating to a “hold” rating in a research note on Friday, September 1st.

VIVUS, Inc. (NASDAQ:VVUS) opened at 0.976 on Tuesday. The firm has a market cap of $103.27 million, a PE ratio of 3.148 and a beta of 0.96. VIVUS, Inc. has a 12-month low of $0.86 and a 12-month high of $1.47. The stock has a 50 day moving average of $0.96 and a 200 day moving average of $1.08.

VIVUS Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Want to see what other hedge funds are holding VVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VIVUS, Inc. (NASDAQ:VVUS).

Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.